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Background
Bipolar disorder is a life-long condition associated with
frequent relapses of symptoms and clinicians often use
combinations of psychotropic agents to treat their
patients. Second generation antipsychotics are a frequent
choice in antimanic pharmacologic treatment. The evi-
d e n c es u g g e s t st h a tf o ra c u t em a n i aac o m b i n a t i o no f
lithium or valproate and an atypical antipsychotic is the
most effective approach. Paliperidone extended-release
(ER) is approved for treatment of acute schizophrenia
and for maintenance treatment of schizophrenia. It has
-probably as a result of its pharmacokinetic profile-
shown robust efficacy, and a favorable tolerability in
multiple trials for the treatment of schizophrenia. Our
goal was to assess its efficacy and tolerability as acute
and maintenance of effect therapy in patients with bipo-
lar I disorder experiencing manic or mixed episodes
while on a mood stabilizer.
Materials and methods
Six hospitalized patients (2 men and 4 women) with
average age 35.6 years and average duration of illness
7.2 years, with acute bipolar I mania (2 of them with a
mixed episode) were put on paliperidone (3 patients on
6 mg and 3 patients on 9 mg). They were all receiving a
mood stabilizer (3 were on valproate, 2 on lithium, and
one on topiramate) although compliance was partial in
at least 4 of the cases. The primary outcome measure
was the mean change in the Young Mania Rating Scale
(at baseline average: 40,3) and secondary measures
included the 21-item Hamilton Rating Scale for Depres-
sion (HAM-D-21) and Clinical Global Impressions-Bipo-
lar Version [(CGI-BP), at baseline average: 5,4] at Week
4 (average YMRS: 14 and CGI-BP: 3), 8 (average YMRS:
11 and CGI-BP: 2,4), and 16(average YMRS: 11 and
CGI-BP: 2,2).
Results
Paliperidone ER provided improvement of acute mania
within 4 days, continuing over 4 weeks and sustained
over 16 weeks in 5 of our 6 patients. It was discontinued
in one at day 8 due to worsening of her symptoms. Pali-
peridone was generally well tolerated and helped
patients achieve and maintain remission without occur-
rence of depressive symptoms. In 2 of the patients on
9 mg, paliperidone was lowered to 6 mg after 8 weeks
without recurrence of symptoms. No patient developed
major depression.
Conclusions
Well tolerated and effective therapies for bipolar mania
are required. It is well known that patients with bipolar
disorder appear more sensitive to antipsychotics. Pali-
peridone provided in our small sample significant
improvement of acute mania and maintained its effect
for 4 months. Paliperidone ER may be a safe and effec-
tive treatment option for acute mania and provide addi-
tional benefit over monotherapy for the management of
the manic phase but also for control of mood symptoms
in the long run, particularly in preventing manic
relapses. It should be noticed that our patients suffered
moderate to severe manic episodes, 4 of them with psy-
chotic features (Patients 1, 2, 4,6), and had to be hospi-
talized for them. This could partially explain why the
addition of an antipsychotic improved rapidly their
symptomatology. Studies with exclusively nonpsychotic
acute or mixed episodes should be conducted.
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